Joining back on the Daily Dive is Bruce Linton, founder and former CEO of Canopy Growth Corporation (TSX: WEED). He gives us an update fresh from stepping down from Gage Growth (CSE: GAGE), the details behind the termination of merger between Red Light Holland (CSE: TRIP) and Creso Pharma (ASX: CPH), and a potential tech project he’s working on. Further, he also shares his view on the outlook of the cannabis industry and its legalization, specifically in New York.
Creso Pharma is an ASX-listed issuer with operations focused on the use of cannabis and hemp across Canada, Europe, Latin America and Australia. In Canada, the company operates its licensed producer, Mernova Medicinal, in Nova Scotia, which focuses on high quality cannabis production. It’s European operations meanwhile are based in Switzerland, where it focuses on its Animal Health, Nutraceutical, and Cosmetics divisions.
FULL DISCLOSURE: Creso Pharma is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Creso Pharma on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
Gold Price Is The US Dollar’s Enemy – The Daily Dive feat Russell Starr of Trillium Gold
Returning to the Daily Dive is Russell Starr of Trillium Gold (TSXV: TGM), whom sits...